Citations (130)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hyojin Eom, Neha Kaushik, Ki-Chun Yoo, Jin-Kyoung Shim, Munjin Kwon, Mi-Young Choi, Taeyoung Yoon, Seok-Gu Kang & Su-Jae Lee. (2018) MerTK mediates STAT3–KRAS/SRC-signaling axis for glioma stem cell maintenance. Artificial Cells, Nanomedicine, and Biotechnology 46:sup2, pages 87-95.
Read now
Read now
Vincenzo Di Nunno, Marta Cubelli & Francesco Massari. (2017) The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. Expert Review of Precision Medicine and Drug Development 2:3, pages 169-175.
Read now
Read now
Bénédicte FAUVEL & Aziz Yasri. (2014) Antibodies directed against receptor tyrosine kinases. mAbs 6:4, pages 838-851.
Read now
Read now
Articles from other publishers (127)
Sandip P. Dholakia, Mukesh N. Kher, Anu Sharma, Romil S. Sangani & Dipen K. Sureja. 2024. Nanotechnology and In Silico Tools. Nanotechnology and In Silico Tools
233
251
.
Tara L. Peters, Nan Chen, Logan C. Tyler, Anh T. Le, Anastasios Dimou & Robert C. Doebele. (2023)
Intrinsic resistance to
ROS1
inhibition in a patient with
CD74‐ROS1
mediated by
AXL
overexpression
. Thoracic Cancer 14:33, pages 3259-3265.
Crossref
Crossref
Kaisa E. Happonen, Patrick G. Burrola & Greg Lemke. (2023) Regulation of brain endothelial cell physiology by the TAM receptor tyrosine kinase Mer. Communications Biology 6:1.
Crossref
Crossref
Ali Arash Anoushirvani, Arezoo Jafarian Yazdi, Sanaz Amirabadi, Sahar Ahmadi Asouri, Rana Shafabakhsh, Amirhossein Sheida, Maryam Sadat Hosseini Khabr, Ameneh Jafari, Seyed Saeed Tamehri Zadeh, Michael R. Hamblin, Leila Kalantari, Sayyed Alireza Talaei Zavareh & Hamed Mirzaei. (2023) Role of non-coding RNAs in neuroblastoma. Cancer Gene Therapy 30:9, pages 1190-1208.
Crossref
Crossref
Chengsheng Zhou, Xiaoshuang Gan, Shandong Sun, Lei Wang, Yong Zhang & Jicheng Zhang. (2023) Construction of an efferocytosis-related long non-coding ribonucleic acid scoring system to predict clinical outcome and immunotherapy response in pancreatic adenocarcinoma. Biochemistry and Biophysics Reports 35, pages 101540.
Crossref
Crossref
Daria Apostolo, Luciana L. Ferreira, Alice Di Tizio, Barbara Ruaro, Filippo Patrucco & Mattia Bellan. (2023) A Review: The Potential Involvement of Growth Arrest-Specific 6 and Its Receptors in the Pathogenesis of Lung Damage and in Coronavirus Disease 2019. Microorganisms 11:8, pages 2038.
Crossref
Crossref
Sheena Bhalla, Farjana J. Fattah, Chul Ahn, Jessica Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel McCracken, David Micklem, Rolf A. Brekken & David E. Gerber. (2023) Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer. Lung Cancer 182, pages 107291.
Crossref
Crossref
Varsha Gadiyar, Gopi Patel, Jesse Chen, Dominico Vigil, Nan Ji, Veronica Campbell, Kirti Sharma, Yatao Shi, Matthew M. Weiss, Raymond B. Birge & Viralkumar Davra. (2023) Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders. Frontiers in Immunology 14.
Crossref
Crossref
Chao Pan, Zhijian Su, Honghui Xie, Yanyang Ning, Shuangjing Li & Haibo Xiao. (2022) Hsa_circ_0081069 facilitates tongue squamous cell carcinoma progression by modulating MAP2K4 expression via miR-634. Odontology 111:2, pages 474-486.
Crossref
Crossref
Manon Barthe, Leslie Hertereau, Noura Lamghari, Hanan Osman-Ponchet & Véronique M. Braud. (2023) Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?. International Journal of Molecular Sciences 24:7, pages 6253.
Crossref
Crossref
Janik Engelmann, Jennifer Zarrer, Victoria Gensch, Kristoffer Riecken, Nikolaus Berenbrok, The Vinh Luu, Antonia Beitzen-Heineke, Maria Elena Vargas-Delgado, Klaus Pantel, Carsten Bokemeyer, Somasekhar Bhamidipati, Ihab S. Darwish, Esteban Masuda, Tal Burstyn-Cohen, Emily J. Alberto, Sourav Ghosh, Carla Rothlin, Eric Hesse, Hanna Taipaleenmäki, Isabel Ben-Batalla & Sonja Loges. (2022) Regulation of bone homeostasis by MERTK and TYRO3. Nature Communications 13:1.
Crossref
Crossref
Shuang Wu, Min Liao, Minxiong Li, Mingming Sun, Ning Xi & Youlin Zeng. (2022) Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation. RSC Medicinal Chemistry 13:10, pages 1246-1264.
Crossref
Crossref
Yeejin Jeon, Hwankyu Kang, Yeongin Yang, Dongsik Park, Baejung Choi, Jeongjun Kim, Jaeseung Kim & Kiyean Nam. (2022) A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment. Cancers 14:19, pages 4821.
Crossref
Crossref
Yun Beom Sang, Joo-Hang Kim, Chang-Gon Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho & Sun Min Lim. (2022) The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges. Frontiers in Oncology 12.
Crossref
Crossref
Mandana Hunter, Krista J. Spiller, Myrna A. Dominique, Hong Xu, Francis W. Hunter, Terry C. Fang, Rebecca G. Canter, Christopher J. Roberts, Richard M. Ransohoff, John Q. Trojanowski & Virginia M.-Y. Lee. (2021) Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery. Acta Neuropathologica Communications 9:1.
Crossref
Crossref
Yifan Zhang, Yiru Wang, Jie Ding & Ping Liu. (2021) Efferocytosis in multisystem diseases (Review). Molecular Medicine Reports 25:1.
Crossref
Crossref
Li-Wei Sun, Shao-Hsuan Kao, Shun-Fa Yang, Shang-Wun Jhang, Yi-Chen Lin, Chien-Min Chen & Yi-Hsien Hsieh. (2021) Corosolic Acid Attenuates the Invasiveness of Glioblastoma Cells by Promoting CHIP-Mediated AXL Degradation and Inhibiting GAS6/AXL/JAK Axis. Cells 10:11, pages 2919.
Crossref
Crossref
Shobha Dagamajalu, D. A. B. Rex, Akhina Palollathil, Rohan Shetty, Guruprasad Bhat, Lydia W. T. Cheung & T. S. Keshava Prasad. (2020) A pathway map of AXL receptor-mediated signaling network. Journal of Cell Communication and Signaling 15:1, pages 143-148.
Crossref
Crossref
Chao-Ju Chen & Yu-Peng Liu. (2021) MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. Pharmaceuticals 14:2, pages 130.
Crossref
Crossref
Aukie Hooglugt, Miesje M. van der Stoel, Reinier A. Boon & Stephan Huveneers. (2021) Endothelial YAP/TAZ Signaling in Angiogenesis and Tumor Vasculature. Frontiers in Oncology 10.
Crossref
Crossref
Yunxiang Zhou, Yali Wang, Hailong Chen, Yanyan Xu, Yi Luo, Yongchuan Deng, Jianmin Zhang & Anwen Shao. (2021) Immuno-oncology: are TAM receptors in glioblastoma friends or foes?. Cell Communication and Signaling 19:1.
Crossref
Crossref
Xuefei Zhou, Xiangrui Liu & Leaf Huang. (2020) Macrophage‐Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials 31:5, pages 2006220.
Crossref
Crossref
Rossella Di Stasi, Lucia De Rosa & Luca D. D’Andrea. (2020) Therapeutic aspects of the Axl/Gas6 molecular system. Drug Discovery Today 25:12, pages 2130-2148.
Crossref
Crossref
Danielle McCullough, Cristina Atofanei, Emily Knight, Steven A. Trim & Carol M. Trim. (2020) Kinome scale profiling of venom effects on cancer cells reveals potential new venom activities. Toxicon 185, pages 129-146.
Crossref
Crossref
Justus M. Huelse, Diana M. Fridlyand, Shelton Earp, Deborah DeRyckere & Douglas K. Graham. (2020) MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacology & Therapeutics 213, pages 107577.
Crossref
Crossref
Karin Juliane Pelizzaro Rocha-Brito, Emanuella Maria Barreto Fonseca, Breno Germano de Freitas Oliveira, Ângelo de Fátima & Carmen Veríssima Ferreira-Halder. (2020) Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency. Bioorganic Chemistry 100, pages 103881.
Crossref
Crossref
Josephine A. Taverna, Chia-Nung Hung, Daniel T. DeArmond, Meizhen Chen, Chun-Lin Lin, Pawel A. Osmulski, Maria E. Gaczynska, Chiou-Miin Wang, Nicholas D. Lucio, Chih-Wei Chou, Chun-Liang Chen, Alia Nazarullah, Shellye R. Lampkin, Lianqun Qiu, David J. Bearss, Steven Warner, Clifford J. Whatcott, Lars Mouritsen, Mark Wade, Steven Weitman, Ruben A. Mesa, Nameer B. Kirma, Wei-Ting Chao & Tim H.-M. Huang. (2020) Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. Cancer Research 80:7, pages 1551-1563.
Crossref
Crossref
Nellie K. McDaniel, Samantha R. Fischbach, Olivia J. Ondracek, Noah B. Welke, Mari Iida & Deric L. Wheeler. 2020. Improving the Therapeutic Ratio in Head and Neck Cancer. Improving the Therapeutic Ratio in Head and Neck Cancer
159
192
.
Inae Jeong, Jayoung Song, Song Yi Bae & Sang Kook Lee. (2019) Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer. Journal of Cancer Prevention 24:4, pages 217-223.
Crossref
Crossref
Chenjing Zhu, Yuquan Wei & Xiawei Wei. (2019) AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. Molecular Cancer 18:1.
Crossref
Crossref
Yiren Xiao, Hongjuan Zhao, Lei Tian, Rosalie Nolley, Anh N. Diep, Anne Ernst, Katherine C. Fuh, Yu Rebecca Miao, Rie von Eyben, John T. Leppert, James D. Brooks, Donna M. Peehl, Amato J. Giaccia & Erinn B. Rankin. (2019) S100A10 Is a Critical Mediator of GAS6/AXL–Induced Angiogenesis in Renal Cell Carcinoma. Cancer Research 79:22, pages 5758-5768.
Crossref
Crossref
Yingying Li, Qianqian Fang, Xinxing Miao, Xiuyan Zhang, Yun Zhao, Jun Yan, Yiqiu Zhang, Renfei Wu, Baoqing Nie, Michael Hirtz & Jian Liu. (2019) Aptamer Conformation-Cooperated Enzyme-Assisted Surface-Enhanced Raman Scattering Enabling Ultrasensitive Detection of Cell Surface Protein Biomarkers in Blood Samples. ACS Sensors 4:10, pages 2605-2614.
Crossref
Crossref
Takeshi Jimbo, Mana Hatanaka, Takahiro Komatsu, Tomoe Taira, Kentaro Kumazawa, Naoyuki Maeda, Takashi Suzuki, Masahiro Ota, Noriyasu Haginoya, Takeshi Isoyama & Kosaku Fujiwara. (2019) DS-1205b, a novel selective inhibitor of AXL kinase, blocks resistance to EGFR-tyrosine kinase inhibitors in a non-small cell lung cancer xenograft model. Oncotarget 10:50, pages 5152-5167.
Crossref
Crossref
Miki Furukawa, Xintao Wang, Hiroshi Ohkawara, Masahiko Fukatsu, Lobna Alkebsi, Hiroshi Takahashi, Kayo Harada-Shirado, Akiko Shichishima-Nakamura, Satoshi Kimura, Kazuei Ogawa & Takayuki Ikezoe. (2019) A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. Blood Advances 3:14, pages 2128-2143.
Crossref
Crossref
Aurélie Ginisty, Lisa Oliver, Patricia Arnault, François Vallette, Omar Benzakour & Valérie Coronas. (2019) The vitamin K-dependent factor, protein S, regulates brain neural stem cell migration and phagocytic activities towards glioma cells. European Journal of Pharmacology 855, pages 30-39.
Crossref
Crossref
Cheng Huang, Yu-Ling Huang, Chia-Chi Wang, Yi-Ling Pan, Yu-Heng Lai & Hsiu-Chen Huang. (2019) Ampelopsins A and C Induce Apoptosis and Metastasis through Downregulating AxL, TYRO3, and FYN Expressions in MDA-MB-231 Breast Cancer Cells. Journal of Agricultural and Food Chemistry 67:10, pages 2818-2830.
Crossref
Crossref
Kei Namba, Kazuhiko Shien, Yuta Takahashi, Hidejiro Torigoe, Hiroki Sato, Takahiro Yoshioka, Tatsuaki Takeda, Eisuke Kurihara, Yusuke Ogoshi, Hiromasa Yamamoto, Junichi Soh, Shuta Tomida & Shinichi Toyooka. (2019)
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
EGFR
-Mutant Non–Small Cell Lung Cancer Cells
. Molecular Cancer Research 17:2, pages 499-507.
Crossref
Crossref
Marion Poirier, Mahendra Awale, Matthias A. Roelli, Guy T. Giuffredi, Lars Ruddigkeit, Lasse Evensen, Amandine Stooss, Serafina Calarco, James B. Lorens, Roch‐Philippe Charles & Jean‐Louis Reymond. (2018) Identifying Lysophosphatidic Acid Acyltransferase β (LPAAT‐β) as the Target of a Nanomolar Angiogenesis Inhibitor from a Phenotypic Screen Using the Polypharmacology Browser PPB2. ChemMedChem 14:2, pages 224-236.
Crossref
Crossref
Bapi Gorain, Subrat Kumar Bhattamishra, Hira Choudhury, Utpal Nandi, Manisha Pandey & Prashant Kesharwani. 2019. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer
39
75
.
Min Jung Choi, Eun Joo Roh, Wooyoung Hur, So Ha Lee, Taebo Sim, Chang-Hyun Oh, Sun-Hwa Lee, Jong Seung Kim & Kyung Ho Yoo. (2018) Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 28:23-24, pages 3761-3765.
Crossref
Crossref
Sherri Smart, Eleana Vasileiadi, Xiaodong Wang, Deborah DeRyckere & Douglas Graham. (2018) The Emerging Role of TYRO3 as a Therapeutic Target in Cancer. Cancers 10:12, pages 474.
Crossref
Crossref
Nellie K. McDaniel, Christopher T. Cummings, Mari Iida, Justus Hülse, Hannah E. Pearson, Eleana Vasileiadi, Rebecca E. Parker, Rachel A. Orbuch, Olivia J. Ondracek, Noah B. Welke, Grace H. Kang, Kurtis D. Davies, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp, Paul M. Harari, Randall J. Kimple, Deborah DeRyckere, Douglas K. Graham & Deric L. Wheeler. (2018) MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Molecular Cancer Therapeutics 17:11, pages 2297-2308.
Crossref
Crossref
Thomas A. Werfel & Rebecca S. Cook. (2018) Efferocytosis in the tumor microenvironment. Seminars in Immunopathology 40:6, pages 545-554.
Crossref
Crossref
Bridget Shafit-Zagardo, Ross C. Gruber & Juwen C. DuBois. (2018) The role of TAM family receptors and ligands in the nervous system: From development to pathobiology. Pharmacology & Therapeutics 188, pages 97-117.
Crossref
Crossref
Luke A. Law, Douglas K. Graham, Jorge Di Paola & Brian R. Branchford. (2018) GAS6/TAM Pathway Signaling in Hemostasis and Thrombosis. Frontiers in Medicine 5.
Crossref
Crossref
B.R. Branchford, T.J. Stalker, L. Law, G. Acevedo, S. Sather, C. Brzezinski, K.M. Wilson, K. Minson, A.B. Lee‐Sherick, P. Davizon‐Castillo, C. Ng, W. Zhang, K.B. Neeves, S.R. Lentz, X. Wang, S.V. Frye, H. Shelton EarpIIIIII, D. DeRyckere, L.F. Brass, D.K. Graham & J.A. Di Paola. (2018) The small‐molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. Journal of Thrombosis and Haemostasis 16:2, pages 352-363.
Crossref
Crossref
Yen-Lin Chen, Yi-Ting Tsai, Ting-Ting Chao, Yi-No Wu, Meng-Chuan Chen, Ying-Hung Lin, Chun-Hou Liao, Shang-Shing P. Chou & Han-Sun Chiang. (2018) DAPK and CIP2A are involved in GAS6/AXL-mediated Schwann cell proliferation in a rat model of bilateral cavernous nerve injury. Oncotarget 9:5, pages 6402-6415.
Crossref
Crossref
Guoan Zhang, Meng Wang, Hongli Zhao & Wen Cui. (2017) Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review). Oncology Letters.
Crossref
Crossref
Carmela Dantas-Barbosa, Tom Lesluyes, François Le Loarer, Fréderic Chibon, Isabelle Treilleux, Jean-Michel Coindre, Pierre Meeus, Mehdi Brahmi, Olivia Bally, Isabelle Ray-Coquard, Marie-Pierre Sunyach, Axel Le Cesne, Olivier Mir, Sylvie Bonvalot, Maud Toulmonde, Antoine Italiano, Pierre Saintigny, Myriam Jean-Denis, Francoise Ducimetiere, Dominique Ranchere, Hiba El Sayadi, Laurent Alberti & Jean-Yves Blay. (2017) Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. British Journal of Cancer 117:12, pages 1787-1797.
Crossref
Crossref
Diana J. Uribe, Edward K. Mandell, Adam Watson, Jesse D. Martinez, Jonathan A. Leighton, Sourav Ghosh & Carla V. Rothlin. (2017) The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer. PLOS ONE 12:7, pages e0179979.
Crossref
Crossref
Masahiro Seike, Cheol-Hong Kim, Fenfei Zou, Rintaro Noro, Mika Chiba, Arimi Ishikawa, Shinobu Kunugi, Kaoru Kubota & Akihiko Gemma. (2017) AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier. Oncology Reports 37:6, pages 3261-3269.
Crossref
Crossref
Wilhem Leconet, Myriam Chentouf, Stanislas du Manoir, Clément Chevalier, Audrey Sirvent, Imade Aït-Arsa, Muriel Busson, Marta Jarlier, Nina Radosevic-Robin, Charles Theillet, Dany Chalbos, Jean-Max Pasquet, André Pèlegrin, Christel Larbouret & Bruno Robert. (2017) Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clinical Cancer Research 23:11, pages 2806-2816.
Crossref
Crossref
Shaojie Bi, Chunyan Wang, Yixin Li, Wei Zhang, Juan Zhang, Zhaopeng Lv & Junxia Wang. (2017) LncRNA-MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma. Tumor Biology 39:5, pages 101042831769979.
Crossref
Crossref
Eun-Hee Lee, Eun-Mi Kim, Kon-Young Ji, A-Reum Park, Ha-Rim Choi, Hwa-Youn Lee, Su-Man Kim, Byung Yeoup Chung, Chul-Hong Park, Hyo Jin Choi, Young-Hyeh Ko, Hyoung-Woo Bai & Hyung-Sik Kang. (2017) Axl acts as a tumor suppressor by regulating LIGHT expression in T lymphoma. Oncotarget 8:13, pages 20645-20655.
Crossref
Crossref
Soichiro Uehara, Yuichi Fukuzawa, Tomohiko Matuyama & Katuhiro Gotoh. (2017) Role of Tyro3, Axl, and Mer Receptors and Their Ligands (Gas6, and Protein S) in Patients with Hepatocellular Carcinoma. Journal of Cancer Therapy 08:02, pages 112-130.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
9
56
.
Mohd Firdaus Che Mat, Nor Azian Abdul Murad, Kamariah Ibrahim, Norfilza Mohd Mokhtar, Wan Zurinah Wan Ngah, Roslan Harun & Rahman Jamal. (2016) Silencing of PROS1 induces apoptosis and inhibits migration and invasion of glioblastoma multiforme cells. International Journal of Oncology 49:6, pages 2359-2366.
Crossref
Crossref
Jose Manuel Ruiz-Morales & Daniel Y.C. Heng. (2016) Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology 8:6, pages 338-347.
Crossref
Crossref
Anand Balupuri, Pavithra K. Balasubramanian & Seung Joo Cho. (2016) Determination of structural requirements of Mer kinase inhibitors and binding interaction analysis using in silico approaches. Medicinal Chemistry Research 25:12, pages 3021-3029.
Crossref
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Crossref
Erinn Rankin & Amato Giaccia. (2016) The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers 8:11, pages 103.
Crossref
Crossref
Sheng-Biao Wang, Mu-Tian Cui, Xiao-Feng Wang, Emika Ohkoshi, Masuo Goto, De-Xuan Yang, Linna Li, Shoujun Yuan, Susan L. Morris-Natschke, Kuo-Hsiung Lee & Lan Xie. (2016) Synthesis, biological evaluation, and physicochemical property assessment of 4-substituted 2-phenylaminoquinazolines as Mer tyrosine kinase inhibitors. Bioorganic & Medicinal Chemistry 24:13, pages 3083-3092.
Crossref
Crossref
Ying Hu, Xiao-ping Liu, Xiao-xia Liu, Yan-fang Zheng, Wei-fang Liu, Ming-lian Luo, Hui Gao, Ying Zhao & Li Zou. (2016) Role of axl in preeclamptic EPCs functions. Journal of Huazhong University of Science and Technology [Medical Sciences] 36:3, pages 395-401.
Crossref
Crossref
D J Pinato, S Chowdhury & J Stebbing. (2015) TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene 35:21, pages 2684-2686.
Crossref
Crossref
L Zhou, X-D Liu, M Sun, X Zhang, P German, S Bai, Z Ding, N Tannir, C G Wood, S F Matin, J A Karam, P Tamboli, K Sircar, P Rao, E B Rankin, D A Laird, A G Hoang, C L Walker, A J Giaccia & E Jonasch. (2015) Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene 35:21, pages 2687-2697.
Crossref
Crossref
Zammam Areeb, Stanley S. Stylli, Thomas M. B. Ware, Nicole C. Harris, Lipi Shukla, Ramin Shayan, Lucia Paradiso, Bo Li, Andrew P. Morokoff, Andrew H. Kaye & Rodney B. Luwor. (2016) Inhibition of glioblastoma cell proliferation, migration and invasion by the proteasome antagonist carfilzomib. Medical Oncology 33:5.
Crossref
Crossref
Julia Onken, Robert Torka, Sören Korsing, Josefine Radke, Irina Krementeskaia, Melina Nieminen, Xi Bai, Axel Ullrich, Frank Heppner & Peter Vajkoczy. (2016)
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion
in vitro
and
in vivo
. Oncotarget 7:9, pages 9876-9889.
Crossref
Crossref
Tamara S. Rodems, Mari Iida, Toni M. Brand, Hannah E. Pearson, Rachel A. Orbuch, Bailey G. Flanigan & Deric L. Wheeler. (2016) Adaptive responses to antibody based therapy. Seminars in Cell & Developmental Biology 50, pages 153-163.
Crossref
Crossref
Insoon Chang, Aasia O. Rehman & Cun-Yu Wang. 2016. Targeting Oral Cancer. Targeting Oral Cancer
71
99
.
Aarif Ahsan. 2016. Lung Cancer and Personalized Medicine. Lung Cancer and Personalized Medicine
137
153
.
KYUNG-CHAN KIM, SUK-HWAN BAEK & CHUHEE LEE. (2015) Curcumin-induced downregulation of Axl receptor tyrosine kinase inhibits cell proliferation and circumvents chemoresistance in non-small lung cancer cells. International Journal of Oncology 47:6, pages 2296-2303.
Crossref
Crossref
Caitlin D. May, Jeannine Garnett, XiaoYan Ma, Sharon M. Landers, Davis R. Ingram, Elizabeth G. Demicco, Ghadah A. Al Sannaa, Tona Vu, Lixia Han, Yi Zhang, Christine M. Kivlin, Svetlana Bolshakov, Azad Abul Kalam, Juehui Liu, Fuguo Zhou, Dominique Broccoli, Wei-Lien Wang, Alexander J. Lazar, Raphael E. Pollock, Dina Lev & Keila E. Torres. (2015) AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer 15:1.
Crossref
Crossref
Zhenzhou Wu, Fan Bai, Liyun Fan, Wenshuai Pang, Ruiyu Han, Juan Wang, Yueping Liu, Xia Yan, Huijun Duan & Lingxiao Xing. (2015) Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas. Human Pathology 46:12, pages 1935-1944.
Crossref
Crossref
Anand Balupuri, Pavithra K. Balasubramanian & Seung Joo Cho. (2015) Molecular modeling study on Mer kinase inhibitors using 3D-QSAR and docking approaches. Medicinal Chemistry Research 24:10, pages 3730-3742.
Crossref
Crossref
Christopher T. Cummings, Weihe Zhang, Kurtis D. Davies, Gregory D. Kirkpatrick, Dehui Zhang, Deborah DeRyckere, Xiaodong Wang, Stephen V. Frye, H. Shelton Earp & Douglas K. Graham. (2015) Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics 14:9, pages 2014-2022.
Crossref
Crossref
Lavina Ahmed, Hawa Nalwoga, Jarle B. Arnes, Henry Wabinga, David R. Micklem & Lars A. Akslen. (2015) Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women. APMIS 123:8, pages 688-696.
Crossref
Crossref
NAM-YI KIM, HWA-YOUNG LEE & CHUHEE LEE. (2015) Metformin targets Axl and Tyro3 receptor tyrosine kinases to inhibit cell proliferation and overcome chemoresistance in ovarian cancer cells. International Journal of Oncology 47:1, pages 353-360.
Crossref
Crossref
Song Yi Bae, Ji-Young Hong, Hye-Jung Lee, Hyen Joo Park & Sang Kook Lee. (2015) Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer. Oncotarget 6:12, pages 10146-10160.
Crossref
Crossref
Amanda A Hill, Jacqueline Carrico, Deborah DeRyckere & Douglas K Graham. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
8
.
Carla V. Rothlin, Eugenio A. Carrera-Silva, Lidia Bosurgi & Sourav Ghosh. (2015) TAM Receptor Signaling in Immune Homeostasis. Annual Review of Immunology 33:1, pages 355-391.
Crossref
Crossref
YOUNG-AH SUH, SE-YOUNG JO, HWA-YOUNG LEE & CHUHEE LEE. (2015) Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells. International Journal of Oncology 46:3, pages 1405-1411.
Crossref
Crossref
Yixin Li, Xiqian Wang, Shaojie Bi, Kun Zhao & Chao Yu. (2015) Inhibition of Mer and Axl receptor tyrosine kinases leads to increased apoptosis and improved chemosensitivity in human neuroblastoma. Biochemical and Biophysical Research Communications 457:3, pages 461-466.
Crossref
Crossref
Zhuang Yu, Xianchao Li, Cuizhu Ge, Hongzong Si, Lianhua Cui, Hua Gao, Yunbo Duan & Honglin Zhai. (2014) 3D-QSAR modeling and molecular docking study on Mer kinase inhibitors of pyridine-substituted pyrimidines. Molecular Diversity 19:1, pages 135-147.
Crossref
Crossref
Emmy D.G. Fleuren, Melissa H.S. Hillebrandt-Roeffen, Uta E. Flucke, D. Maroeska W.M. te Loo, Otto C. Boerman, Winette T.A. van der Graaf & Yvonne M.H. Versleijen-Jonkers. (2014)
The role of AXL and the
in vitro
activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
. Oncotarget 5:24, pages 12753-12768.
Crossref
Crossref
David R Micklem, Magnus Blø, Petra Bergström, Erlend Hodneland, Crina Tiron, Torill Høiby, Christine Gjerdrum, Ola Hammarsten & James B Lorens. (2014) Flow cytometry-based functional selection of RNA interference triggers for efficient epi-allelic analysis of therapeutic targets. BMC Biotechnology 14:1.
Crossref
Crossref
W Leconet, C Larbouret, T Chardès, G Thomas, M Neiveyans, M Busson, M Jarlier, N Radosevic-Robin, M Pugnière, F Bernex, F Penault-Llorca, J-M Pasquet, A Pèlegrin & B Robert. (2013) Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene 33:47, pages 5405-5414.
Crossref
Crossref
Fei Xu, Hongling Li & Yong Sun. (2014) Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma. Biochemical and Biophysical Research Communications 454:4, pages 566-571.
Crossref
Crossref
Catherine Wilson, Xiaofen Ye, Thinh Pham, Eva Lin, Sara Chan, Erin McNamara, Richard M. Neve, Lisa Belmont, Hartmut Koeppen, Robert L. Yauch, Avi Ashkenazi & Jeff Settleman. (2014) AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs. Cancer Research 74:20, pages 5878-5890.
Crossref
Crossref
Erinn B. RankinKatherine C. FuhLaura CastelliniKartik ViswanathanElizabeth C. FingerAnh N. DiepEdward L. LaGoryMihalis S. KariolisAndy ChanDavid Lindgren, Håkan Axelson, Yu R. MiaoAdam J. Krieg & Amato J. Giaccia. (2014) Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proceedings of the National Academy of Sciences 111:37, pages 13373-13378.
Crossref
Crossref
Toni M. Brand, Mari Iida, Andrew P. Stein, Kelsey L. Corrigan, Cara M. Braverman, Neha Luthar, Mahmoud Toulany, Parkash S. Gill, Ravi Salgia, Randall J. Kimple & Deric L. Wheeler. (2014) AXL Mediates Resistance to Cetuximab Therapy. Cancer Research 74:18, pages 5152-5164.
Crossref
Crossref
Mohammad Hojjat-Farsangi. (2014) Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies. International Journal of Molecular Sciences 15:8, pages 13768-13801.
Crossref
Crossref
M A Cichoń, Z Szentpetery, M P Caley, E S Papadakis, I C Mackenzie, C H Brennan & E A O'Toole. (2013) The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma. Oncogene 33:32, pages 4185-4192.
Crossref
Crossref
Kuo-Chou Chiu, Chien-Hsing Lee, Shyun-Yeu Liu, Chi-Tai Yeh, Ren-Yeong Huang, Da-Yo Yuh, Jen-Chan Cheng, Yu-Ting Chou & Yi-Shing Shieh. (2014) Protumoral effect of macrophage through Axl activation on mucoepidermoid carcinoma. Journal of Oral Pathology & Medicine 43:7, pages 538-544.
Crossref
Crossref
Gareth D. Hyde, Rebecca F. Taylor, Nick Ashton, Samantha J. Borland, Hon Sing Geoffrey Wu, Andrew P. Gilmore & Ann E. Canfield. (2014) Axl Tyrosine Kinase Protects against Tubulo-Interstitial Apoptosis and Progression of Renal Failure in a Murine Model of Chronic Kidney Disease and Hyperphosphataemia. PLoS ONE 9:7, pages e102096.
Crossref
Crossref
Chien-Hsing Lee, Shyun-Yeu Liu, Kuo-Chou Chou, Chi-Tai Yeh, Shine-Gwo Shiah, Ren-Yeong Huang, Jen-Chan Cheng, Ching-Yu Yen & Yi-Shing Shieh. (2013) Tumor-Associated Macrophages Promote Oral Cancer Progression Through Activation of the Axl Signaling Pathway. Annals of Surgical Oncology 21:3, pages 1031-1037.
Crossref
Crossref
Kyung-Chan KimChuHee Lee. (2014) Reversal of Cisplatin Resistance by Epigallocatechin Gallate Is Mediated by Downregulation of Axl and Tyro 3 Expression in Human Lung Cancer Cells. The Korean Journal of Physiology & Pharmacology 18:1, pages 61.
Crossref
Crossref
Philip D. Dunne, Darragh G. McArt, Jaine K. Blayney, Murugan Kalimutho, Samanda Greer, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Maurice Loughrey, Keara Redmond, Daniel B. Longley, Manuel Salto-Tellez, Patrick G. Johnston & Sandra Van Schaeybroeck. (2014) AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer. Clinical Cancer Research 20:1, pages 164-175.
Crossref
Crossref
Huaping TangJing YangDing Ren ShenDeepa CalamburMark WitmerSophie WuBrian CarpenterYaqun ZhangMian GaoKeith ConstantineLitao ZhangMary Ellen Cvijic. (2014) High-Throughput High-Content Imaging Assays for Identification and Characterization of Selective AXL Pathway Inhibitors. ASSAY and Drug Development Technologies 12:1, pages 80-86.
Crossref
Crossref
Angela M. Pierce & Amy K. Keating. (2014) TAM receptor tyrosine kinases: Expression, disease and oncogenesis in the central nervous system. Brain Research 1542, pages 206-220.
Crossref
Crossref
Sridhar Nimmagadda, Mrudula Pullambhatla, Ala Lisok, Chaoxin Hu, Anirban Maitra & Martin G Pomper. (2014) Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications 443:2, pages 635-640.
Crossref
Crossref
Ashley N. Rettew, Patrick J. Getty & Edward M. Greenfield. 2014. Current Advances in Osteosarcoma. Current Advances in Osteosarcoma
47
66
.
Weihe Zhang, Dehui Zhang, Michael A. Stashko, Deborah DeRyckere, Debra Hunter, Dmitri Kireev, Michael J. Miley, Christopher Cummings, Minjung Lee, Jacqueline Norris-Drouin, Wendy M. Stewart, Susan Sather, Yingqiu Zhou, Gregory Kirkpatrick, Mischa Machius, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye & Xiaodong Wang. (2013) Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors. Journal of Medicinal Chemistry 56:23, pages 9683-9692.
Crossref
Crossref
Masashi Ishikawa, Makoto Sonobe, Ei Nakayama, Masashi Kobayashi, Ryutaro Kikuchi, Jiro Kitamura, Naoto Imamura & Hiroshi Date. (2012) Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients. Annals of Surgical Oncology 20:S3, pages 467-476.
Crossref
Crossref
Ténin Traoré, Andrea Cavagnino, Nicolas Saettel, François Radvanyi, Sandrine Piguel, Isabelle Bernard-Pierrot, Véronique Stoven & Michel Legraverend. (2013) New aminopyrimidine derivatives as inhibitors of the TAM family. European Journal of Medicinal Chemistry 70, pages 789-801.
Crossref
Crossref
Lutfi Suleiman, Claude Négrier & Habib Boukerche. (2013) Protein S: A multifunctional anticoagulant vitamin K-dependent protein at the crossroads of coagulation, inflammation, angiogenesis, and cancer. Critical Reviews in Oncology/Hematology 88:3, pages 637-654.
Crossref
Crossref
Keith M. Giles, Felicity C. Kalinowski, Patrick A. Candy, Michael R. Epis, Priscilla M. Zhang, Andrew D. Redfern, Lisa M. Stuart, Gregory J. Goodall & Peter J. Leedman. (2013) Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. Molecular Cancer Therapeutics 12:11, pages 2541-2558.
Crossref
Crossref
Sandra Christoph, Deborah DeRyckere, Jennifer Schlegel, J. Kimble Frazer, Lance A. Batchelor, Alesia Y. Trakhimets, Susan Sather, Debra M. Hunter, Christopher T. Cummings, Jing Liu, Chao Yang, Dmitri Kireev, Catherine Simpson, Jacqueline Norris-Drouin, Emily A. Hull-Ryde, William P. Janzen, Gary L. Johnson, Xiaodong Wang, Stephen V. Frye, H. Shelton EarpIIIIII & Douglas K. Graham. (2013)
UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia
In Vitro
and
In Vivo
. Molecular Cancer Therapeutics 12:11, pages 2367-2377.
Crossref
Crossref
Lidia Bosurgi, Jochem H. Bernink, Victor Delgado Cuevas, Nicola Gagliani, Leonel Joannas, Edward T. Schmid, Carmen J. Booth, Sourav Ghosh & Carla V. Rothlin. (2013) Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proceedings of the National Academy of Sciences 110:32, pages 13091-13096.
Crossref
Crossref
Rebecca S. Cook, Kristen M. Jacobsen, Anne M. Wofford, Deborah DeRyckere, Jamie Stanford, Anne L. Prieto, Elizabeth Redente, Melissa Sandahl, Debra M. Hunter, Karen E. Strunk, Douglas K. Graham & H. Shelton EarpIIIIII. (2013) MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. Journal of Clinical Investigation 123:8, pages 3231-3242.
Crossref
Crossref
R M A Linger, R A Cohen, C T Cummings, S Sather, J Migdall-Wilson, D H G Middleton, X Lu, A E Barón, W A Franklin, D T Merrick, P Jedlicka, D DeRyckere, L E Heasley & D K Graham. (2012) Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 32:29, pages 3420-3431.
Crossref
Crossref
Jing Liu, Weihe Zhang, Michael A. Stashko, Deborah DeRyckere, Christopher T. Cummings, Debra Hunter, Chao Yang, Chatura N. Jayakody, Nancy Cheng, Catherine Simpson, Jacqueline Norris-Drouin, Susan Sather, Dmitri Kireev, William P. Janzen, H. Shelton Earp, Douglas K. Graham, Stephen V. Frye & Xiaodong Wang. (2013) UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry 65, pages 83-93.
Crossref
Crossref
Floor A.M. Duijkers, Jules P.P. Meijerink, Rob Pieters & Max M. van Noesel. (2013) Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration. Gene 521:1, pages 62-68.
Crossref
Crossref
Russell S. Taichman, Lalit R. Patel, Rachel Bedenis, Jingcheng Wang, Savannah Weidner, Taibriana Schumann, Kenji Yumoto, Janice E. Berry, Yusuke Shiozawa & Kenneth J. Pienta. (2013) GAS6 Receptor Status Is Associated with Dormancy and Bone Metastatic Tumor Formation. PLoS ONE 8:4, pages e61873.
Crossref
Crossref
Rosa M. Suárez, Franciane Chevot, Andrea Cavagnino, Nicolas Saettel, François Radvanyi, Sandrine Piguel, Isabelle Bernard-Pierrot, Véronique Stoven & Michel Legraverend. (2013) Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation. European Journal of Medicinal Chemistry 61, pages 2-25.
Crossref
Crossref
L N Brandao, A Winges, S Christoph, S Sather, J Migdall-Wilson, J Schlegel, A McGranahan, D Gao, X Liang, D DeRyckere & D K Graham. (2013) Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer Journal 3:1, pages e101-e101.
Crossref
Crossref
Sophie Postel-Vinay & Alan Ashworth. (2012) AXL and acquired resistance to EGFR inhibitors. Nature Genetics 44:8, pages 835-836.
Crossref
Crossref
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D Levine, Jin Kyung Rho, Yun Jung Choi, Chang-Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung-Shin Lee, Vincent A Miller, Maria Arcila, Marc Ladanyi, Philicia Moonsamy, Charles Sawyers, Titus J Boggon, Patrick C Ma, Carlota Costa, Miquel Taron, Rafael Rosell, Balazs Halmos & Trever G Bivona. (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics 44:8, pages 852-860.
Crossref
Crossref
Zhixiang Wu, Amin Moghaddas Gholami & Bernhard Kuster. (2012) Systematic Identification of the HSP90 Regulated Proteome. Molecular & Cellular Proteomics 11:6, pages M111.016675.
Crossref
Crossref
Kurt W. Kohn, Barry R. Zeeberg, William C. Reinhold, Margot Sunshine, Augustin Luna & Yves Pommier. (2012) Gene Expression Profiles of the NCI-60 Human Tumor Cell Lines Define Molecular Interaction Networks Governing Cell Migration Processes. PLoS ONE 7:5, pages e35716.
Crossref
Crossref
Thomas Schmidt, Isabel Ben-Batalla, Alexander Schultze & Sonja Loges. (2011) Macrophage–tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands. Cellular and Molecular Life Sciences 69:9, pages 1391-1414.
Crossref
Crossref
Vyacheslav A. Korshunov. (2011) Axl-dependent signalling: a clinical update. Clinical Science 122:8, pages 361-368.
Crossref
Crossref
Justine Migdall-Wilson, Christine Bates, Jennifer Schlegel, Luis Brandão, Rachel M. A. Linger, Deborah DeRyckere & Douglas K. Graham. (2012) Prolonged Exposure to a Mer Ligand in Leukemia: Gas6 Favors Expression of a Partial Mer Glycoform and Reveals a Novel Role for Mer in the Nucleus. PLoS ONE 7:2, pages e31635.
Crossref
Crossref
Alexis Mollard, Steven L. Warner, Lee T. Call, Mark L. Wade, Jared J. Bearss, Anupam Verma, Sunil Sharma, Hariprasad Vankayalapati & David J. Bearss. (2011) Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors. ACS Medicinal Chemistry Letters 2:12, pages 907-912.
Crossref
Crossref
Marialuisa Sensi, Mara Catani, Giancarlo Castellano, Gabriella Nicolini, Federica Alciato, Gabrina Tragni, Giuseppina De Santis, Ilaria Bersani, Giancarlo Avanzi, Antonella Tomassetti, Silvana Canevari & Andrea Anichini. (2011) Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor Kinase. Journal of Investigative Dermatology 131:12, pages 2448-2457.
Crossref
Crossref
Maeva Dufies, Arnaud Jacquel, Nathalie Belhacene, Guillaume Robert, Thomas Cluzeau, Fréderic Luciano, Jill Patrice Cassuto, Sophie Raynaud & Patrick Auberger. (2011) Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget 2:11, pages 874-885.
Crossref
Crossref
Jonathan W. Riess & Joel W. Neal. (2011) Targeting FGFR, Ephrins, Mer, MET, and PDGFR-α in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:11, pages S1797-S1798.
Crossref
Crossref
Anupam Verma, Steven L. Warner, Hariprasad Vankayalapati, David J. Bearss & Sunil Sharma. (2011) Targeting Axl and Mer Kinases in Cancer. Molecular Cancer Therapeutics 10:10, pages 1763-1773.
Crossref
Crossref